Market Newsdesk

TOKYO, Dec. 08, 2020 (GLOBE NEWSWIRE) — NHK WORLD-JAPAN, Japan’s international 24-hour English-language television channel, became part of Telus’ channel lineup on Tuesday, December 8^th, 2020. Telus is the first operator in Canada to include NHK WORLD-JAPAN on their platform.

“Carriage on Telus in Canada is an important milestone for NHK WORLD-JAPAN, and we are delighted that our channel is now available to Canadian viewers,” said Mr. Shiromoto Masaru, president and CEO of Japan International Broadcasting (JIB), the worldwide distributor of NHK WORLD-JAPAN. “By bringing our original and diverse programming to Telus, we will now have the ability to reach even more viewers, making our wide variety of programs more accessible to new audiences.”

Telus plans to provide the NHK WORLD-JAPAN channel in HD for free to its viewers in western Canada for 3 months. It will be included in the News International package on Telus’ IPTV service, Optik TV.

NHK WORLD-JAPAN features original television programming from NHK, the sole public broadcaster in Japan, and delivers diverse programming featuring hourly live international news from Tokyo and overseas, along with programs on current affairs, lifestyle, culture, food, travel, sports, technology, science, and history, with the Japan and Asian perspective.

About NHK WORLD-JAPAN

NHK (Japan Broadcasting Corporation) is Japan’s sole public broadcaster, operating the nation’s largest domestic and international television network. In Japan, NHK broadcasts six TV channels including 4K and 8K along with three radio stations. NHK also transmits two international television channels, NHK WORLD-JAPAN (English, HD, 24/7) and NHK WORLD PREMIUM (Japanese, HD, 24/7), as well as international radio services in eighteen languages. NHK WORLD-JAPAN reaches over 380 million households in 160 countries and regions via local satellite and cable TV providers. Online live streaming and VOD (video-on-demand) services through the free mobile app and the website, give viewers access to NHK WORLD-JAPAN anywhere and anytime. You can also connect through Roku, Apple TV and Amazon Fire TV. Presenting an extensive range of Asia-centered programming, NHK WORLD-JAPAN is your window to Japan, Asia, and the rest of the world. For more details, visit nhk.jp/world.

About Japan International Broadcasting, Inc.

Japan International Broadcasting Inc. (JIB), a subsidiary of NHK, is responsible for the worldwide distribution of the HD English language news/lifestyle channel “NHK WORLD-JAPAN,” as well as the HD Japanese language channel “NHK WORLD PREMIUM.” Currently, the two channels are broadcast around the world on three international plus domestic satellites in their respective markets and reach households, hotels and others via DTH, cable, IPTV, and terrestrial broadcast.

Contact:

Boyle Public Affairs for NHK WORLD-JAPAN
Krista Van Lewen
415-608-0263
krista@boylepublicaffairs.com

BERLIN and DENVER, Dec. 08, 2020 (GLOBE NEWSWIRE) — ezeep by ThinPrint, a leading provider of cloud printing solutions, today announced the release of the ezeep mobile print app, the industry-standard in cloud-based mobile printing. ezeep’s mobile print app enable easy printing from iPhones, iPads, or Android smartphones to any ezeep connected network printer to optimize workplace security and productivity.

In today’s continuously changing work environments, companies of all sizes are considering enterprise mobility applications that can meet the demands of today’s workforce, making printing from a mobile device an essential need to stay productive. ezeep’s unique cloud-based approach allows for simple setup and manageability, ensuring security and privacy for the company and the end user.

With ezeep mobile print, IT administrators can easily access the ezeep Admin Portal to assign printers to individual users or user groups. Mobile users can then use the app on their iPhone, iPad, or Android device to print documents to any assigned printer. This is all done with a cloud-based approach, eliminating complex networking architecture and routing challenges and expenses. From a security standpoint, all connections from the mobile device stay separate from the company’s firewalls and networks, and all documents and print jobs are transmitted with state-of-the-art encryption, reducing security threats.

“ezeep has set another milestone towards drastically simplified printing in both personal and professional environments, making printing as easy as making a phone call from your mobile device,” said Christoph Hammer, Senior Vice President Cloud Services at ThinPrint. “Users now have the freedom to use their mobile devices to trigger the print job whenever they wish, ensuring productivity and security does not falter.”

ezeep’s mobile app not only provides users with access to all printers assigned via the ezeep portal with their iPads, iPhones, and Android devices, but also includes features to enhance usability. All options available in the print dialog, such as paper sizes, page selection, color/black and white, and duplex, are at their disposal. If documents and images are to be exported directly from any application, they can simply use the open-in/share feature of the respective app.

ezeep’s mobile print apps also complement any existing EMM/MDM solution. The apps can be securely and easily distributed via enterprise mobility systems such as MobileIron, Workspace ONE (AirWatch), Citrix XenMobile, Cortado MDM, SOPHOS, or BlackBerry (Good) or downloaded from the Apple App Store and Google Play Store.

For more information about ezeep mobile print visit https://www.ezeep.com/solution/mobile-printing/.

About ezeep
:

The future of printing is ezeep. With ezeep, printing is dramatically simplified, enabling any device to print to any printer – whether with the ezeep printer driver from PC or Mac, via app for smartphones and tablets or even by web-based drag & drop for the occasional user.

Consumers print unlimited and – naturally – free-of-charge to their own printers and, depending on the provider, free or at a cost to external printers. This makes printing as easy as making a phone call, eliminating the need for any user support. Companies can lower the infrastructure demands on their printer setups in branch offices worldwide, thanks to ezeep, drastically simplifying their administration. With this, the total costs for deploying printers is significantly reduced.

Coworking spaces, universities, exhibition grounds, train stations, airports and kiosks can not only make their printers publicly available with just a single click, but also charge for printing with ease. The same applies to private users or cafés which want to share their printers with others. Printers are thereby transformed into sources of income, not costs. Open interfaces enable integrations with existing solutions, such as for user and resource management, cost control or compliance monitoring for maximum cost savings via automation. A constantly growing ecosystem of standard integrations by development partners makes these benefits also available to non-technical users.

By reducing costs and removing all technical requirements, whilst providing the ability to use third-party printers at any time, ezeep ensures that in the future people will be able to print from almost every location quickly and easily, for whatever reason they might have. ezeep is committed to minimizing the CO2 footprint of printing and ensuring that printed paper can be a meaningful, productive and responsible alternative to screen-based information consumption. For more information, please visit: www.ezeep.com. 

Media Contacts:

North America: Kendra Westerkamp, VisiTech PR
Phone: +1-303-752-3552, email: [email protected]

Rest of World:
Silke Kluckert, Public Relations Manager
Phone: +49 30 39493166, email: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d28f29d7-8ce3-4dee-8bdf-bf00fdfe1983

This Product is Comprised of Raw Linden Honey Infused with 500mg CBD / Each Jar Contains 20 Servings (25mg CBD per Serving)

 NEW YORK, NY, Dec. 08, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced a new product offering to help ensure the expansion and diversification of the Company’s proprietary product offerings.  This is in response to the Company’s fast growing E-Commerce business segment as well as the continually increasing customer base.

After evaluating numerous potential new product offerings, the Company has decided to launch this CBD Infused Linden Honey (“CBD Honey”) product.  This new product will be infused with 500mg of CBD per Jar (“Unit”) and each jar contains 20 servings (25mg CBD per serving).  This product will also be Kosher Certified and of the highest quality.  The Manufacturer’s Suggested Retail Price (“MSRP”) is expected to be set at $49.99 USD per Jar.  This CBD Honey (16 oz. Jars) will be available exclusively on the Company’s E-Commerce Website (www.taurigum.com).

Raw Linden Honey is a tough honey to produce as the Linden trees are only in bloom 7-10 days annually. The honey has been described as having a very fresh aroma, described as: minty, menthol, camphor, balsamic, etc. Excellent honey for tea, desserts, muffins, hot cereal – you name it!  The blooming season for Linden trees is generally the first week in July in the Northern Hemisphere. 

Tauriga’s CEO Seth M. Shaw: “The Company has been both pleased and excited by the sharp increase in its online E-Commerce business.  However, even more exciting, is the continual growth of the Company’s prospective customer base.  As the customer base increases, so does the Company’s desire to expand and diversify product offerings to support this enhanced audience.  It is our policy to carefully listen to the advice and recommendations of our customers.  In this spirit, the Company has decided to launch this innovative CBD Honey product. Additionally, more products are on the way!” 

In other news, the Company is close to achieving an important corporate milestone.  The Company’s Instagram Page, @taurigum, has secured more than 9,700 Followers.  Once the 10,000 Followers threshold is reached, the Company believes that there will be a positive effect on its E-Commerce Business.  

Link to @taurigum Instagram Page:

Link: https://www.instagram.com/taurigum/

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Tauri-Gum™ Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, are its two ongoing biotechnology initiatives.  The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.   

On October 6, 2020, the Company announced that it has been approved to operate as a U.S. Government Vendor (CAGE CODE # 8QXV4)

On October 7, 2020 the Company disclosed a Strategic Alliance with Think BIG, LLC, Social Impact Startup Founded by CJ Wallace, Son of Christopher “The Notorious B.I.G.” Wallace.

The Company is headquartered in New York City and operates a regional office in Barcelona, Spain.  In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER — Forward-Looking Statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in  forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.

555 Madison Avenue, 5th Floor

New York, NY  10022

Chief Executive Officer

Mr. Seth M. Shaw

Email: [email protected]

cell # (917) 796 9926

Instagram: @taurigum

Twitter: @SethMShaw

Corp. Website:  www.tauriga.com

E-Commerce Website:  www.taurigum.com

Attachment

• Dec 8 PR Image

BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) — Boston Cell Standards, announced today that it will present the results of a Canadian national study that tested the first system of reference materials for standardization of estrogen receptor (ER) testing for breast cancer. The study is being presented at the San Antonio Breast Cancer Symposium, which takes place virtually December 8 – 11.

As many previously published studies have demonstrated, high variability exists in the performance of ER testing when comparing different laboratories. For the first time, however, this new study also included immunohistochemistry (IHC) calibrators that defined a clear unit of measure—molecules of ER per cell. Using these first units of measure, traceable to a NIST standard, analytical sensitivities of individual ER assays were quantified. These new testing tools clearly demonstrated a defined analytic sensitivity threshold at which ER testing becomes suboptimal, missing most weakly positive cases. Although all the clinical ramifications of this threshold cannot be known without further studies, the new measurement tool provides critical information that can be used to track variability among laboratories, reagent lots, and even day-to-day runs, potentially lowering error rates in IHC laboratories. Termed “IHCalibrators,” these new tools were developed by Boston Cell Standards in collaboration with the National Institute of Standards and Technology (NIST). They are the first of their kind in the immunohistochemistry (IHC) industry.

The study was performed by the Canadian Immunohistochemistry Quality Control (CIQC) program. CIQC offered Canadian ER testing laboratories the opportunity to test 80 different breast cancer patient samples, as a check to verify that they obtain the correct answers. Also included were the new reference materials, capable of measuring the laboratory’s analytical sensitivity of their ER test. The performance of the new tool was correlated with the laboratory’s ability to accurately distinguish positive and negative patient samples.  

“The new tool showed a highly significant positive correlation between measured analytical sensitivity of the laboratories’ ER IHC tests with their ability to identify tumors that express low levels of estrogen receptor,” said Dr. Emina Torlakovic, Royal University Hospital, Saskatoon, SK, who directed the study. “While breast cancer patients with ER-high positive tumors would receive the correct test result and treatment irrespective of the measured analytical sensitivity, breast cancer patients with ER-low positive tumors had widely varying test results that depended on the laboratory’s test sensitivity.” Dr. Torlakovic continued. “The study did not directly examine the tests and treatments in the 80 different cases. However, the varying survey results would be expected to lead to different treatment decisions, depending on the laboratory performing the test.”

Dr. Steven Bogen, President and CEO of Boston Cell Standards, which developed the analytical tools said, “Traceability of measurement to a higher order reference is the standard of practice in all other types of clinical laboratory testing but has never before been feasible for immunohistochemistry testing. We expect its availability will lead to significant improvements in immunohistochemistry test accuracy and reproducibility. The data presented in the San Antonio Breast Cancer Symposium validate the reference materials for standardizing ER testing in the diagnosis of breast cancer.”

About Boston Cell Standards

Boston Cell Standards is the first and only company to develop and manufacture standardized reference materials in the immunohistochemistry industry. Its mission is to improve patient outcomes by ensuring that immunohistochemistry test results are accurate and reproducible regardless of where or when tests are performed. Laboratory reference materials are essential for that purpose. We bring together outstanding physicians, scientists, and staff in a creative and supportive environment with the goal of spurring groundbreaking advances that can be applied to the laboratory setting. For more information, visit http://bostoncellstandards.com/.

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Raytheon Technologies Corporation f/k/a Raytheon Company (NYSE: RTX, RTN) between February 10, 2016 and October 27, 2020, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 29, 2020.

To join the class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=raytheon-technologies-corporation&id=2507 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email [email protected] for information on the class action.

如果您想加入这个集体诉讼案，请在这里提交您的信息。http://zhanginvestorlaw.com/join-action-form/?slug=raytheon-technologies-corporation&id=2507

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: Raytheon had inadequate disclosure controls and procedures and internal control over financial reporting; Raytheon had faulty financial accounting; as a result, Raytheon misreported its costs regarding Raytheon’s Missiles & Defense business since 2009; as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice; and as a result, Defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Lead plaintiff status is not required to seek compensation.  You may retain counsel of your choice.  You may remain an absent class member and take no action at this time.

Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.

Zhang Investor Law P.C.
99 Wall Street, Suite 232
New York, New York 10005
[email protected]
tel: (800) 991-3756